Xia Lizi, de Vries Henk, IJzerman Ad P, Heitman Laura H
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands.
Purinergic Signal. 2016 Mar;12(1):115-26. doi: 10.1007/s11302-015-9485-0. Epub 2015 Dec 9.
Scintillation proximity assay (SPA) is a radio-isotopic technology format used to measure a wide range of biological interactions, including drug-target binding affinity studies. The assay is homogeneous in nature, as it relies on a "mix and measure" format. It does not involve a filtration step to separate bound from free ligand as is the case in a traditional receptor-binding assay. For G protein-coupled receptors (GPCRs), it has been shown that optimal binding kinetics, next to a high affinity of a ligand, can result in more desirable pharmacological profiles. However, traditional techniques to assess kinetic parameters tend to be cumbersome and laborious. We thus aimed to evaluate whether SPA can be an alternative platform for real-time receptor-binding kinetic measurements on GPCRs. To do so, we first validated the SPA technology for equilibrium binding studies on a prototypic class A GPCR, the human adenosine A1 receptor (hA1R). Differently to classic kinetic studies, the SPA technology allowed us to study binding kinetic processes almost real time, which is impossible in the filtration assay. To demonstrate the reliability of this technology for kinetic purposes, we performed the so-called competition association experiments. The association and dissociation rate constants (k on and k off) of unlabeled hA1R ligands were reliably and quickly determined and agreed very well with the same parameters from a traditional filtration assay performed simultaneously. In conclusion, SPA is a very promising technique to determine the kinetic profile of the drug-target interaction. Its robustness and potential for high-throughput may render this technology a preferred choice for further kinetic studies.
闪烁邻近分析(SPA)是一种放射性同位素技术形式,用于测量广泛的生物相互作用,包括药物-靶点结合亲和力研究。该分析本质上是均相的,因为它依赖于“混合并测量”的形式。它不像传统的受体结合分析那样需要过滤步骤来分离结合态和游离配体。对于G蛋白偶联受体(GPCR),已经表明,除了配体具有高亲和力外,最佳的结合动力学可以产生更理想的药理学特征。然而,评估动力学参数的传统技术往往繁琐且费力。因此,我们旨在评估SPA是否可以作为GPCR实时受体结合动力学测量的替代平台。为此,我们首先在一种典型的A类GPCR——人腺苷A1受体(hA1R)上验证了SPA技术用于平衡结合研究。与经典动力学研究不同,SPA技术使我们能够几乎实时地研究结合动力学过程,这在过滤分析中是不可能的。为了证明该技术用于动力学目的的可靠性,我们进行了所谓的竞争结合实验。未标记的hA1R配体的结合和解离速率常数(k on和k off)能够可靠且快速地确定,并且与同时进行的传统过滤分析得到的相同参数非常吻合。总之,SPA是一种非常有前景的技术,可用于确定药物-靶点相互作用的动力学特征。其稳健性和高通量潜力可能使该技术成为进一步动力学研究的首选。